1Ramdeen, S. J., 1Usoro, N., 1Giordano, K., 1Garza, P. E., 2Quadri, O., 3Esan, T. E., and *1Olanrewaju,A. A.
1Texas State University, Medical Laboratory Science Program San Marcos, TX USA
2Northern Illinois University, Chemistry and Biochemistry Analytical Lab, Dekalb, IL USA
3Rosalind Franklin University of Medicine and Science, Chicago, IL USA *Correspondence to: dep112@txstate.edu; Phone: +1 571-228-0537
Abstract:
Background: Dengue, a mosquito-borne virus infection, reportedly affected over 7.6 million people in early 2024, subsequently leading to approximately 3000 deaths. Dengue is primarily spread by Aedes (A. aegypti and A. albopictus) mosquitoes. There is currently no clinically approved preventive vaccine against Dengue virus (DENV), and according to the Center for Disease Control (CDC), the only acceptable vaccine for DENV is Dengvaxia, which has efficacy and safety issues. This makes it unsuitable for use against DENV. Drug repurpose is an alternative approach for the discovery of novel therapeutics. Continue reading “Discovery of potential antiviral compounds against Dengue virus using virtual screening and physicochemical profiling from zinc database”